Cargando…

The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies

BACKGROUND: High-quality evidence for whether the use of renin–angiotensin–aldosterone system (RAAS) inhibitors worsens clinical outcomes for patients with coronavirus disease 2019 (COVID-19) is lacking. The present study aimed to evaluate the effect of RAAS inhibitors on disease severity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Kai, Cao, Lanxin, Xuan, Nanxia, Huang, Tiancha, Tian, Baoping, Cui, Wei, Zhang, Gensheng, Zhang, Shufang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212589/ https://www.ncbi.nlm.nih.gov/pubmed/36785646 http://dx.doi.org/10.1016/j.jointm.2022.05.004

Ejemplares similares

Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
por: Ssentongo, Anna E, et al.
Publicado: (2020)

Diagnostic value of aldosterone to renin ratio calculated by plasma renin activity or plasma renin concentration in primary aldosteronism: a meta-analysis
por: Liu, Zhenjie, et al.
Publicado: (2022)

Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
por: Kaur, Upinder, et al.
Publicado: (2021)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
por: Kurdi, Amanj, et al.
Publicado: (2022)

The Prognostic Accuracy of National Early Warning Score 2 on Predicting Clinical Deterioration for Patients With COVID-19: A Systematic Review and Meta-Analysis
por: Zhang, Kai, et al.
Publicado: (2021)

National Early Warning Score Does Not Accurately Predict Mortality for Patients With Infection Outside the Intensive Care Unit: A Systematic Review and Meta-Analysis
por: Zhang, Kai, et al.
Publicado: (2021)

Effect of preoperative renin-angiotensin system blockade on vasoplegia after cardiac surgery: A systematic review with meta-analysis
por: Noubiap, Jean Jacques, et al.
Publicado: (2022)

Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies
por: Kunutsor, Setor K., et al.
Publicado: (2017)

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
por: Vejakama, P., et al.
Publicado: (2011)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
por: Loader, Jordan, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
por: Hernandez, Adrian V., et al.
Publicado: (2023)

Effects of catheter‐based renal denervation on renin‐aldosterone system, catecholamines, and electrolytes: A systematic review and meta‐analysis
por: Yang, Xiangyu, et al.
Publicado: (2022)

Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
por: Chu, Chang, et al.
Publicado: (2020)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
por: Moon, Ju-Young
Publicado: (2013)

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
por: Gnanenthiran, Sonali R., et al.
Publicado: (2022)

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Renin-Angiotensin Aldosterone System and Hypertension: Current Approaches and Future Directions
por: Flack, John M., et al.
Publicado: (2007)

Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis
por: Wu, Yucheng, et al.
Publicado: (2021)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study
por: Zhu, Xiao-Xu, et al.
Publicado: (2023)

Lipid Profiles in Primary Aldosteronism Compared with Essential Hypertension: Propensity-Score Matching Study
por: Moon, Sun Joon, et al.
Publicado: (2021)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
por: Andersen, Karl
Publicado: (2009)

The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension
por: Wang, Hui-Bo, et al.
Publicado: (2015)

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension
por: Simko, Fedor, et al.
Publicado: (2018)

Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy
por: Ward, Jessica L., et al.
Publicado: (2022)

Activation of the Renin–Angiotensin–Aldosterone System Is Attenuated in Hypertensive Compared with Normotensive Pregnancy
por: Shoemaker, Robin, et al.
Publicado: (2023)

Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care
por: Haroon, Shamil, et al.
Publicado: (2021)

Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta‐Analysis of Randomized Trials and Propensity Score–Matched Studies
por: Fong, Khi Yung, et al.
Publicado: (2022)

The effect of medication on the aldosterone‐to‐renin ratio. A critical review of the literature
por: Alnazer, Rawan M., et al.
Publicado: (2021)

Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study
por: Volterrani, Maurizio, et al.
Publicado: (2020)

Confounders of the aldosterone‐to‐renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature
por: Veldhuizen, Gregory P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j2dm8hhr8c59lqjrcd0f3nob0i